PACIFIC-AMI: Factor XIa inhibitor asundexian on top of DAPT after acute MI

PACIFIC-AMI: Factor XIa inhibitor asundexian on top of DAPT after acute MI – #ESCCongress 2022

by michaelg August 29, 2022

Video by PCR via YouTube
Go to Source
PACIFIC-AMI: Factor XIa inhibitor asundexian on top of DAPT after acute MI – #ESCCongress 2022

Ali Nazmi Calik asks trial investigator John Alexander about the design and results of the PACIFIC-AMI phase 2 trial, which revealed no increase in bleeding versus placebo.

More news on the ESC Congress 2022 Interventional cardiology perspective on PCRonline: https://www.pcronline.com/News/Whats-new-on-PCRonline/2022/ESC-2022/PCRonline-ESC-Congress-2022

Go to Source

T-PASS: Less than 1-month DAPT followed by… by Michaelg
RTC - Radial versus femoral access for coronary… by Michaelg
INVICTUS - Rivaroxaban vs VKA for rheumatic atrial… by Michaelg
COVID-PACT - Antithrombotic therapy in critically… by Michaelg
ARREST trial: Expedited transfer to a cardiac arrest… by Michaelg
The randomized PICSO-AMI-I trial:… by Michaelg

# education # innovation # innovative

PACIFIC-AMI: Factor XIa inhibitor asundexian on top of DAPT after acute MI – #ESCCongress 2022

Related Posts: